Evaluating whether Tonix Pharmaceuticals (NASDAQ: TNXP) represents a favorable buy or sell decision requires weighing its clinical pipeline developments in fibromyalgia, central nervous system disorders, and infectious disease vaccines against historical operating losses, dilution risks from frequent capital raises, and small-cap biotech volatility. Healthcare analysts recommend reviewing individual risk tolerance and clinical trial catalysts before trading.